Program
enlicitide chloride
Also written as “Enlicitide Chloride” and “[¹⁴C]Enlicitide chloride”.
Its studies are mostly in Hypercholesterolemia, led by Merck.
Furthest: phase 1, since Oct 1, 20214 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 40 open or running | phase 1since Oct 1, 2021 | Oct 1, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 1, 2021First study: phase 1 study in Moderate Renal ImpairmentFirst studyNCT05070390 · 18 enrolled · United States
- Oct 21, 20242 phase 1 studiesNCT06655311, NCT06658626
- Feb 3, 2025Phase 1 study in HealthyNCT06814106 · 37 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06814106Healthy · China | 1 | Completed | May 8, 2023 | 37 |
| NCT06658626Healthy · United States | 1 | Completed | Aug 2, 2023 | 8 |
| NCT06655311Hypercholesterolemia · United States | 1 | Completed | Jan 2, 2024 | 56 |
| NCT05070390Moderate Renal Impairment · United States | 1 | Completed | May 3, 2023 | 18 |
How it is read
Names in the registry
- “Enlicitide Chloride”, 3 entries
- “[¹⁴C]Enlicitide chloride”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.